FLASCO

Member’s Publications

Home » Current News & Publications » Member’s Publications

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V W  X  Y  Z


A

Aghajanian Carol, Chen Lee-may, Darus Christopher J., Filiaci Virginia L., Makker Vicky, Moxley Katherine, Sutton Gregory. Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study 0229N. 16 April 2015.

Ahmad Sarfraz, Ali Ghazanfar, Banks Robert K., Edwards John R., Finkler Neil J., Holloway Robert W., Ingersoll Susan B., McGann Hasina C., Srivastava Milan, Stavitzski Nicole M.. Cellular therapy in combination with cytokines improves survival in a xenograft mouse model of ovarian cancer. Springer Science+Business Media New York 2015. Published online: 6 June 2015

Ahmad Sarfraz, Ph.D., Ansari Ammara, M.D., Holloway Robert W., M.D., James Jeffery A., D.O., Jeppson Corinne N., D.O., Robotic-assisted Laparoscopic Resection of Cornual Ectopic Pregnancy: A Case Report. The Journal of Reproductive Medicine. Volume 60, Number 1-2/January-February 2015.

Ahmad S., Boggess  J.F., Dahl A.A., Holloway R.W., Jackson A.L., Sert B.M., Stavitzski, N.M. Robot-assisted versus open radical hysterectomy: A multi-institutional experience for early-stage cervical cancer. December 2015.

Ahmad Sarfraz, Chen Ping, Han Lingfei, Li Fang, Lu Jiahong, Kong Fanfei, Ma Ge, Sun Jing, Tao Jie, Wang Wei, Shuai Wen, Ye Lei, Zhao Dong, Zhou Qian, Zhu Jianlong, Zhu Yiping. AAV–sBTLA facilitates HSP70 vaccine-triggered prophylactic antitumor immunity against a murine melanoma pulmonary metastasis model in vivo. Cancer Letters Volume 354, Issue 2, Pages 398–406. August 18, 2014.

Ahmad Sarfraz PhD, Conri Vanessa, MD,Fastrez Maxime, MD, Goffin Frederic, MD, Holloway Robert, MD, Hudry Delphine, MD, Lambaudie Eric, MD, PhD, Le ́curu Fabrice, MD, PhD,Leguevaque Pierre, MD, PhD, Narducci Fabrice, MD, Ponce Jordi, MD, PhD, Tucher Elisabeth, MD, Zanagnolo Vanna, MD with the collaboration of the SERGS Group. Robotically Assisted Para-aortic Lymphadenectomy: Surgical Results A Cohort Study of 487 Patients. International Journal of Gynecological Cancer & Volume 25, Number 3, March 2015.

Ahmad Sarfraz, PhD, Gupta Sarika, MD, Holloway Robert W., MD, Wisner Ketura Preya A., DO. Indications and Techniques for Robotic Pelvic and Para-Aortic Lymphadenectomy in Gynecologic Oncology. Journal of Surgical Oncology 2015;112:782–789.

Ahmad Sarfraz, Holloway Robert W., James Jeffrey A., Jeppson Corinne N., Rakowski Joseph A., Stavitzski Nicole M.. Robotic transperitoneal infra-renal aortic lymphadenectomy in early-stage endometrial cancer. Gynecologic Oncology 136 (2015) 285–292. 27 December 2014.

Ahmad Sarfraz, Kendrick James E. and Holloway Robert W.. Robotic pelvic and aortic lymphadenectomy for gynecologic malignancies – one approach. Bereitgestellt von | De Gruyter / TCS Angemeldet | 46.30.84.116.

Akerley Wallace L., MD, Berek Jonathan S., MD, DeMars Leslie R., MD, Edwards Robert P., MD, Friccius-Quecke Hilke, PhD, Herzog Thomas J., MD, Holloway Robert W., MD, Krasner Carolyn N., MD, Lentz Samuel S., MD, Method Michael W., MD, MPH, MBA, Morris Robert T., MD, Parker Lynn P., MD, Plaxe Steven C., MD, Walker Joan L., MD. Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer: A Phase II Study. International Journal of Gynecological Cancer & Volume 24, Number 9. November 2014.

Al-Badawi IA, Alshankiti H, Ahmad S. Single incision laparoscopic surgery in pregnancy. CRSLS e2014.00404. DOI: 10.4293/CRSLS.2014.00404.

C

Caglevic C, Grassi M, Raez LE, Listi A, Giallombardo M, Bustamante E, Gil-Bazo I, Rolfo C. Nintedanib in non-small cell lung cancer: from preclinical to approval. Ther Adv Respir Dis. 2015 Apr 7. pii: 1753465815579608. [Epub ahead of print] Review.

Chan J. K., Fiorica J. V., Grendys Jr.E. C., Herzog T. J., Holloway R., Orr Jr. J. W.,Tian C., Wang D.. Overview of a chemoresponse assay in ovarian cancer. Clin Transl Oncol (2014) 16:761–769. 2 July 2014.

Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 1; 32(25):2735-43. doi: 10.1200/JCO.2013.54.6309. Epub 2014 Jul 21.PMID:25049329

F

Finkler Neil, Fong Peter C, Garcia Agustin A, Konecny Gottfried E, Kristeleit Rebecca, Mishra Kaushal, Lee Paula S, Lorusso Domenica, Rocconi Rodney P, Squires Matt, Upalawanna Allison, Wang Yongyu. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. www.thelancet.com/oncology Vol 16 June 2015.

G

Gubbi Ajit, Finkler Neil J., Kendrick James E.. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer. Expert review of anticancer therapy 14.10 (2014): 1105-1113.

H

Holloway Robert W., Ahmad Sarfraz, Bigsby Glenn E., Brudie Lorna A., Gubbi Ajit, Gupta Sarika, Stavitzski Nicole M., Takimoto Erica L. Zhu Xiang. Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis. January 2016.

M

Marks, Alan The Physician’s Perspective: A Health Policy Brief on Improving Patient Access to Immuno-Oncology Therapies. The Institute for Patient Access Dis. 2015 October.

Marks, Alan, Iyengar, Sloka. The Physician’s Perspective: A Health Policy on Improving Cancer Patient’s Access to Precision Medicine. The Institute for Patient Access Dis. 2016 May.

P

Passiglia F, Van Der Steen N, Raez LE, Pauwels P, Gil-Bazo I, Santos E, Santini D, Tesoriere G, Russo A, Bronte G, Zwaenepoel K, Cappuzzo F, Rolfo C. The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target? Curr Drug Targets. 2014;15(14):1284-92. Review.

Perez CA, Velez M, Raez LE, Santos ES. Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation. Lung Cancer. 2014 Feb 8. pii: S0169-5002(14)00064-6. doi: 10.1016/j.lungcan.2014.02.001. [Epub ahead of print] Review.

R

Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treat Rev. 2014 Sep; 40(8):990-1004. doi: 10.1016/j.ctrv.2014.05.009. Epub 2014 Jun 6. Review. PMID: 24953979

Rolfo C, Passiglia F, Castiglia M, Raez LE, Germonpre P, Gil-Bazo I, Zwaenepoel K, De Wilde A, Bronte G, Russo A, Van Meerbeeck JP, Van Schil P, Pauwels P. ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it. Transl Lung Cancer Res. 2014 Aug;3(4):250-61. doi: 10.3978/j.issn.2218-6751.2014.03.01. Review

Rolfo C, Sortino G, Smits E, Passiglia F, Bronte G, Castiglia M, Russo A, Santos ES, Janssens A, Pauwels P, Raez LE. Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? Expert Rev Anticancer Ther. 2014 Oct;14(10):1173-87. doi: 10.1586/14737140.2014.952287. Epub 2014 Aug 22. PMID: 25148289.

Rolfo C, Ruiz R, Giovannetti E, Gil-Bazo I, Russo A, Passiglia F, Giallombardo M, Peeters M, Raez LE. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. Expert Opin Investig Drugs. 2015 Nov;24(11):1493-500. doi: 10.1517/13543784.2015.1096344.Epub 2015 Oct 12. PMID:26457764.

Ruiz R, Hunis B, Raez LE. Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines. Curr Oncol Rep. 2014 Sep; 16(9):400. doi: 10.1007/s11912-014-0400-6. PMID: 25030654.

Ruiz R, Raez LE, Rolfo C. Entinostat (SNDX-275) for the treatment of non-small cell lung cancer.  Expert Opin Investig Drugs. 2015;24(8):1101-9. doi: 10.1517/13543784.2015.1056779. Epub 2015 Jun 22. PMID: 26098363

V

Van Der Steen N, Pauwels P, Gil-Bazo I, Castañon E, Raez LE, Cappuzzo F, Rolfo C. cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance. Cancers (Basel). 2015 Mar 25;7(2):556-73. doi: 10.3390/cancers7020556. Review. PMID:25815459.

Who’s Online

There are no users currently online